Vanderbilt-Ingram Cancer Center

Henry-Joyce Cancer Clinic

Nashville, TN

Accepting patients

Mismatched Related vs. Matched Unrelated Donor

A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Learn more
  • Allogeneic Stem Cell Transplant
  • Monoclonal Antibody
  • Phase 3

Accepting patients

Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Learn more
  • Observational Trial
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

ASTX030

A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Learn more
  • DNMT1 Inhibitor
  • Phase 2/3

Accepting patients

Vorinostat for GVHD Prevention

A Phase 1/2 Multi-Center Trial of Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
Learn more
  • Allogeneic Stem Cell Transplant
  • HDAC Inhibitor
  • Phase 1/2

Accepting patients

Maintenance Ruxolitinib

Phase II Study of Maintenance Ruxolitinib After Allogeneic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Complete Remission
Learn more
  • JAK2 Inhibitor
  • Tyrosine Kinase (TK) Inhibitor
  • Maintenance
  • Phase 2

Accepting patients

DFV890

A Phase 1b, Open Label, Multi-center, Dose Optimization and Dose Expansion Study to Assess the Safety and Efficacy of DFV890 in Adult Patients With Myeloid Diseases
Learn more
  • NLRP3 Inhibitor
  • Phase 1

Accepting patients

ABNL-MARRO

The ABNL-MARRO 001 Study: A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes.
Learn more
  • Chemotherapy
  • Phase 1/2
  • Has results

Accepting patients

FHD-286

A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286, as Monotherapy or Combination Therapy, in Subjects With Advanced Hematologic Malignancies
Learn more
  • BRG1 Inhibitor
  • BRM Inhibitor
  • Phase 1
  • Has results

Accepting patients

PedAL Screening

Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
Learn more
  • Phase 1/2

Accepting patients

Eltanexor and Venetoclax

Phase Ib Study of Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Learn more
  • SINE
  • Phase 1